Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF)(IPF Coalition).IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.
Pacific Therapeutics Ltd. (the “Company”) lead drug candidate for fibrosis (progressive scarring of the organ), PTL-202 is a combination of Pentoxifylline (a FDA approved drug used for treating leg cramps) and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant.
As previously announced the company has completed a phase 1 trial of the combination in humans. The positive results from the phase 1 clinical trial and positive pre-clinical results, will lead to further development of the product for treating fibrosis such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis.